Business Daily from THE HINDU group of publications
Tuesday, Nov 11, 2008
ePaper | Mobile/PDA Version | Audio | Blogs
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Announcements
Glenmark Generics drug in US

Mumbai, Nov. 10

Glenmark Generics Ltd (GGL), through its subsidiary in the US, has started the distribution of Morphine Sulfate Oral Concentrate Solution in that market. The product will be the fifth from Glenmark in the pain management segment.

The drug for relief from acute pain is being manufactured for Glenmark in the US through a partnership and distributed directly from GGL's warehouse in New Jersey. Glenmark Pharmaceutical's shares were up 10 per cent, at Rs 336.75 on the BSE on Monday.

GGL is a subsidiary of Mumbaibased Glenmark Pharmaceuticals Ltd, and it was formed when GPL was realigned to focus separately on generics and innovative drugs separately. - Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Lupin to sell cardiac drug

Glenmark Generics drug in US
Binani Ind plans buyback
East Coast Energy secures nod for Rs 600-cr jetty
Monorail project: Challenge for L&T
L&T consortium wins Mumbai monorail deal
MMTC bags Capexil award
McNally Bharat has 87% stake in McNally Sayaji
RIL arm may take 67% stake in KG Gas Network
Delphi Corp to invest Rs 250 cr near Chennai
Aries Agro starts new unit in Lucknow
RHW Hotel expanding presence
Bharat Forge, Alstom to form two joint ventures
Punj Lloyd, Dayim eye infra projects in Saudi Arabia
Murugappa group plans infrastructure biz entry
‘We’ve spooked ourselves into thinking there is a slowdown’
CESC plans Rs 2,000-cr investment to revive distribution network




eWorld
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line